Company
Indivior plc
Headquarters: North Chesterfield, VA, United States
Founded: 1994
Employees: 800
CEO: Mr. Mark Crossley
Market Cap
£1.55 Billion
GBP as of July 1, 2024
US$1.97 Billion
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Indivior plc has the following listings and related stock indices.
Stock: LSE: INDV wb_incandescent
Stock: FSX: 2IV wb_incandescent
Stock: FSX: 2IVA wb_incandescent
Stock: OTC: IZQVF wb_incandescent
Product & Services
Subutex/Subuxone
Key People
Graham Hetherington, Chairman Mark Crossley, CEO
Financials
Revenue: $791 million (2021)
Operating income: $213 million (2021)
Net income: $205 million (2021)